Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Olga Lavynenko, Muhammad Abdul‐Ghani, Mariam Alatrach, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 899-907
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S181-S206
Closed Access | Times Cited: 68
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S59-S85
Closed Access | Times Cited: 18
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 5
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 12
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
David S.H. Bell, Terri Jerkins
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3093-3102
Closed Access | Times Cited: 19
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Siham Abdelgani, Ahmed Khattab, John M. Adams, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 668-675
Open Access | Times Cited: 6
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction
Yip Han Chin, Jieyu Lim, Gwyneth Kong, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1032-1044
Closed Access | Times Cited: 18
Role of anti-diabetic medications in the management of MASLD
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Georgios S. Papaetis, Michalis Picolos, Anastasia Sacharidou
Archives of Medical Science - Atherosclerotic Diseases (2025) Vol. 10, Iss. 1, pp. 1-15
Open Access
Albiflorin inhibits inflammation to improve liver fibrosis by targeting the CXCL12/CXCR4 axis in mice
Lingjie Meng, Huijing Lv, Anli Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects
Aurora Merovci, Brittany Finley, Andrea Hansis‐Diarte, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 5, pp. e004199-e004199
Open Access | Times Cited: 3
Comparative review of algorithms and methods for chemical‐shift‐encoded quantitative fat‐water imaging
Pierre Daudé, Tangi Roussel, Thomas Troalen, et al.
Magnetic Resonance in Medicine (2023) Vol. 91, Iss. 2, pp. 741-759
Open Access | Times Cited: 7
Pioglitazone in diabetic kidney disease: forgotten but not gone
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2022) Vol. 7, Iss. 1, pp. 78-93
Open Access | Times Cited: 11
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
Hong‐Yi Chiu, Shih‐Chang Tsai, Fuu‐Jen Tsai, et al.
In Vivo (2023) Vol. 37, Iss. 3, pp. 1037-1046
Open Access | Times Cited: 6
One‐hour post‐load glucose levels are associated with hepatic steatosis assessed by transient elastography
Francesco Andreozzi, Elettra Mancuso, Elisa Mazza, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 682-689
Open Access | Times Cited: 5
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
Cesare Berra, Roberto Manfrini, Marco Mirani, et al.
Acta Diabetologica (2023) Vol. 60, Iss. 9, pp. 1257-1266
Open Access | Times Cited: 4
The determination of the comparative effect of Ertugliflozin, Pioglitazone, and Metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus.
Adil Khaliq, Haroon Badshah, Yasar Shah, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, et al.
Annals of Military and Health Sciences Research (2024) Vol. 22, Iss. 2
Open Access | Times Cited: 1
Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
Stanley S. Schwartz, Barbara E. Corkey, James R. Gavin, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Automated shape-independent assessment of the spatial distribution of proton density fat fraction in vertebral bone marrow
Tobias Haueise, Norbert Stefan, Tim J. Schulz, et al.
Zeitschrift für Medizinische Physik (2023) Vol. 34, Iss. 3, pp. 436-445
Open Access | Times Cited: 2
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
Konstantinos Malandris, Stylianos Papandreou, Ioannis Avgerinos, et al.
HORMONES (2023) Vol. 22, Iss. 4, pp. 655-664
Open Access | Times Cited: 2
Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
Luisa Barana, Agnès Nelva, P. Scivetti, et al.
Endocrine (2024) Vol. 84, Iss. 2, pp. 412-419
Closed Access
The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
Ayesha Akhtar, Huda Ijaz, Maria Waseem, et al.
Annals of Medicine and Surgery (2024)
Open Access
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
(2024)
Closed Access
Page 1 - Next Page

Scroll to top